Navigation Links
Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
Date:9/10/2007

t of rheumatoid arthritis. In December 2005, the company entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of certain therapeutics, including TRU-015. In addition, Trubion's TRU-016 program targets CD37, an antigen present on B cells, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Subject to satisfactory completion of preclinical testing of TRU-016, the company expects to file an IND for TRU-016 in the second half of 2007. Trubion currently retains all development and commercialization rights for the TRU-016 program. For additional information visit http://www.trubion.com.

Forward-Looking Statements

Certain statements in this release may constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. These statements include, but are not limited to, those related to the company's future clinical development programs and the timing thereof, the company's expected financial and operating results, future clinical development plans, the details of the clinical trials and the results and timing thereof, and the timing of regulatory applications and action. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, risks associated with the company's Wyeth collaboration, including Wyeth's control over development timelines, and the risks associated with conducting additional clinical trials for TRU-015, the uncertainty of the FDA approval process and the therapeutic and commercial value of Trubion's drug candidates; and such other risks as identified in the company's quarterly report on Form 10-Q for the period ended June 30, 2007, and fr
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Diseases largely eradicated in ... returning. Measles was declared eliminated in 2000, yet the ... August 15—the highest incidence in 20 years. In July, ... whooping cough a problem of "epidemic proportions." ... dying from these preventable diseases—in part because some parents ...
(Date:8/29/2014)...  Abaxis, Inc. (NasdaqGS: ABAX ), a ... to the medical, research and veterinary markets, announced today ... Officer, will present at the CL King 12 th ... 9, 2014 at 12:30 p.m. ET. The conference will ... New York City . ...
(Date:8/29/2014)... , August 29, 2014 ... participate in the inaugural Tweetchat taking place in ... Worldwide , organised by UBM Live , ... #CPhIChat is a first of its kind global ... across the supply chain, aimed to stimulate conversations ...
Breaking Medicine Technology:Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 2CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 3
... WIRE)--Jun 28, 2007 - CombinatoRx,Incorporated (NASDAQ: CRXX) ... placebo-controlled clinical trial of,CRx-150 in patients with ... a disease-modifying anti-rheumatic drug,(DMARD) to placebo plus ... the preliminary analysis of this trial, CRx-150 ...
... percent response rate achieved with VELCADE, lenalidomide,and ... -- Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM) today reported ... trials of VELCADE based,therapies that showed consistently ... (CR) rates in newly diagnosed,multiple myeloma (MM) ...
Cached Medicine Technology:CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 2CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 3CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 4CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 5Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 2Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 3Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 4Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 5Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 6Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 7Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 8
(Date:8/29/2014)... 2014 Healthpointe has unveiled its new ... the convenience of visiting with physicians online. Anyone can ... , Healthpointe doctors are always available and happy to ... the doctor can even see the patient’s entire family. ... or she can prescribe medications that are available for ...
(Date:8/29/2014)... August 29, 2014 A recent article ... developed by a Tokyo clothing store for men with gynecomastia, ... of rectifying or diminishing their problem. Board-certified plastic surgeon Dr. ... the problem. While many people only associate male breasts with ... common condition among men of all ages, often starting in ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Highly regarded audiologist ... on important hearing health topics. The four reports are titled:, ... The Secrets to Hearing Aid Success , The Top ... Understanding Auditory Processing Disorder in Children , ... because there is a lot of confusion and misinformation about each ...
(Date:8/29/2014)... August 29, 2014 Healthpointe is pleased ... has joined their practice. Dr. Chuang garners extensive experience ... in minimally-invasive arthroscopic and reconstructive treatments of the knees, ... patients with general and sports-related orthopedic needs. ... medical field. As an Orange County native, he graduated ...
(Date:8/29/2014)... August 29, 2014 Carson Hearing Care ... provide hearing health care tips to local residents on ... section will offer weekly articles from the audiologists at ... including the latest advances in hearing restoration research, new ... The audiologists plan to write a new post on ...
Breaking Medicine News(10 mins):Health News:Virtual Doctor’s Appointments Now Available at Healthpointe 2Health News:New Bra Created for Men with Gynecomastia, But Will It Work? 2Health News:New Bra Created for Men with Gynecomastia, But Will It Work? 3Health News:Charleston SC Audiologist, Dr. Mary Ann Larkin Authors Four New Special Reports on Important Hearing Healthcare Topics 2Health News:Charleston SC Audiologist, Dr. Mary Ann Larkin Authors Four New Special Reports on Important Hearing Healthcare Topics 3Health News:Healthpointe is Honored to Induct Orthopedic Surgeon into Their Team 2Health News:Fort Worth Hearing Aid Leader, Carson Hearing Care, Creates Expert Blog to Discuss Important Hearing Healthcare Topics 2Health News:Fort Worth Hearing Aid Leader, Carson Hearing Care, Creates Expert Blog to Discuss Important Hearing Healthcare Topics 3
... Beautiful ... Smiles Curated by Gen Art, NEW YORK, April 4, ... a new generation of,smile care, Crest Whitestrips Daily Whitening + Tartar ... and protect against,tartar build-up -- Crest Whitestrips and Gen Art have ...
... Adelaide, Australia, will delve into some of the crucial issues ... to be conducted in the joint University of Adelaide/IMVS Centre ... signals in the brain and the reasons why brain tumours ... around how the brain works, and this new research will ...
... Perfect" Score by the American Correctional Association Auditors ... Earns High Praise From Board Chair Romanowicz, ... an exhaustive,three-day audit and examination by the American Correctional ... pleased to report that the Donald W. Wyatt Detention,Facility ...
... HILL, N.C., April 4, 2008 Companies align,commercial ... a,company with an annual sales volume of $10 ... assigned to the early-stage commercialization team along,with approximately ... the ratio is approximately four to three, commercial ...
... and Other Ethnic Minorities at Increased Risk, BALTIMORE, ... J.,Barthelow Classen in The Open Endocrinology Journal shows a ... following the,discontinuation of a single vaccine, a vaccine to ... is a global epidemic of type 2,diabetes and metabolic ...
... children who lead inactive lifestyles are five-to-six times more likely ... degree of danger emerging as early as their teenage years, ... of North Carolina at Chapel Hill. , The findings, published ... looked at a group of children twice first while ...
Cached Medicine News:Health News:The Quest for America's Life in Beautiful Smiles: Captured in Photography 2Health News:The Quest for America's Life in Beautiful Smiles: Captured in Photography 3Health News:Unlocking mysteries of brain cancer, stroke 2Health News:Donald W. Wyatt Detention Facility Scores 3-Year Accreditation and Among Highest Rated in the United States 2Health News:Donald W. Wyatt Detention Facility Scores 3-Year Accreditation and Among Highest Rated in the United States 3Health News:Early-stage Commercialization Success: Pharma Companies Adjust Resources in Light of Industry Changes 2Health News:Vaccine Induced Inflammation Linked to Epidemic of Type 2 Diabetes and Metabolic Syndrome 2Health News:Inactive kids face 6-fold risk of heart disease by teen years, study finds 2
300 L, Racked, Filtered, Pre-sterilized, 96 tips/rack Recommended for 250 and 300 L pipettes....
... false signals and contamination caused by ... Barrier Tips offer performance and economy ... (PCR(a)), radioactive isotopes, tissue culture fluids, ... , ,Promega Barrier Tips are made ...
Diamond Filter Tips play a critical role in preventing aerosol-borne contamination. Also available sterilized (no need to autoclave) and certified free of detectable RNase, DNase, DNA, RNA, and prote...
... Filters are ideal for PCR ... for any work where aerosol ... designed for pipetting DNA/RNA solutions, ... other. For applications requiring absolute ...
Medicine Products: